期刊
PHARMACOLOGY & THERAPEUTICS
卷 113, 期 2, 页码 442-458出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2006.11.002
关键词
nitroxyl; nitric oxide; calcitonin gene-related peptide; thiols; ischemia-reperfusion; vasorelaxation; Angeli's salt; heart failure; platelets; myocardium; inotropy; thrombosis
资金
- Wellcome Trust [067422] Funding Source: Medline
Nitroxyl (HNO), the I-electron reduced and protonated congener of nitric oxide (NO), has received recent attention as a potential pharmacological agent for the treatment of heart failure and as a preconditioning agent for the mitigation of ischemia-reperfusion injury. Interest in the pharmacology and biology of HNO has prompted examination, or in some instances reexamination, of many of its chemical properties. Such studies have provided insight into the chemical basis for the biological effects of HNO, although the biochemical mechanisms for many of these effects remain to be established. In this review, a brief description of the biologically relevant chemistry of HNO is given, followed by a more detailed discussion of the pharmacology and potential toxicology of HNO. (c) 2006 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据